Replies to post #106931 on Amarin Corp Plc (AMRN)

[AVII77]

Given V's safety profile compared with other lipid agents in the market, if Amarin is a "person", it has a serious case of discrimination Vs. the FDA.

Had they continued to approve other drugs based on lipid effects after they lost faith in surrogate outcomes in this space then I would agree with you.

[iwfal]

Given V's safety profile compared with other lipid agents in the market, if Amarin is a "person", it has a serious case of discrimination Vs. the FDA.

Until you've run a big outcomes RCT you don't really know the trade of safety vs efficacy. I'll make the wager that some kind of p<0.1 safety signal pops up (although it may take 5 years before it is acknowledged - because that is the nature of these things. Eg almost 20 years to acknowledge statins cause increase in T2D)